D4.4 Midterm recruitment report – Clinical study 4 - COPD cohort

116019 - RESCEU

REspiratory Syncytial virus Consortium in EUrope

WP4 – Prospective data collection

Lead contributor	Louis Bont (3 – UMC Utrecht (UMCU))
	Email: l.bont@umcutrecht.nl
Other contributors	Joanne Wildenbeest (3 – UMCU)
	Gavin Donaldson, Ryan Thwaites, Peter Openshaw, Jadwiga Wedzicha (6 – Imperial)
	Maarten van den Berge, Ben Ditz (11 – UMCG)

Due date	31/10/2017
Delivery date	31/10/2017
Deliverable type	R
Dissemination level	PU

Description of Work	Version	Date
	V1.0	31/10/2017

Table of contents

Document History

Version	Date	Description
V0.1	29/09/2017	First Draft
V0.2	08/10/2017	Comments
V0.3	20/10/2017	Draft
V1.0	31/10/2017	Final Version

Definitions

Participants of the RESCEU Consortium are referred to herein according to the following codes:

- **UEDIN.** University of Edinburgh (United Kingdom)
- **UA.** Universiteit Antwerpen (Belgium)
- **UMCU.** University Medical Centre Utrecht (Netherlands)
- **UOXF.** The Chancellor, Masters and Scholars of the University of Oxford (United Kingdom)
- **SYNAPSE.** Synapse Research Management Partners S.L. (Spain)
- **Imperial.** Imperial College of Science, Technology and Medicine (United Kingdom)
- **SERGAS.** Servicio Galego de Saúde (Spain)
- **TUCH.** Varsinais-Suomen sairaanhoitopiirin kuntayhtymä (Finland)
- **RIVM.** Rijksinstituut voor Volksgezondheid en Milieu - National Institute for Public Health and the Environment (Netherlands)
- **SSI.** Statens Serum Institut (Denmark)
- **UMCG.** Academisch Ziekenhuis Groningen (Netherlands)
- **PENTA.** Fondazione PENTA for the treatment and care of children with HIV-ONLUS (Italy)
- **AZ.** Astrazeneca AB (Sweden)
- **Pfizer.** Pfizer Limited (United Kingdom)
- **GSK Bio.** GlaxoSmithKline Biologicals S.A. (Belgium)
- **SP.** Sanofi Pasteur (France)
- **JPNV.** Janssen Pharmaceutica, N.V (Belgium)
- **Novavax.** Novavax Inc. (United States of America)

- **Consortium.** The RESCEU Consortium, comprising the above-mentioned legal entities.
- **Consortium Agreement.** Agreement concluded amongst RESCEU participants for the implementation of the Grant Agreement. Such an agreement shall not affect the parties' obligations to the Community and/or to one another arising from the Grant Agreement.
- **COPD.** Chronic Obstructive Pulmonary Disease
- **GOLD.** Global Initiative for Chronic Obstructive Lung Disease
- **Grant Agreement.** The agreement signed between the beneficiaries and the IMI JU for the undertaking of the RESCEU project (116019).
- **Project.** The sum of all activities carried out in the framework of the Grant Agreement.
- **Work plan.** Schedule of tasks, deliverables, efforts, dates and responsibilities corresponding to the work to be carried out, as specified in Annex I to the Grant Agreement.

Publishable Summary

Participants for the COPD cohort study, which is the fourth of the RESCEU clinical studies, will be recruited from the COPD clinic at UMCG and the London COPD cohort at Imperial College.

Participants with COPD (GOLD stage I-IV) will be enrolled in this prospective observational study and undergo a baseline assessment. They will then be monitored for 3 years by filling in a daily symptom diary and 6-monthly visits to the COPD clinic. When they develop symptoms of an exacerbation, they will visit the COPD clinic to have swabs and sputum taken for virological assessment in addition to lung function tests and collection of blood.

The London COPD cohort is a rolling cohort of 200 patients who are trained in reporting of exacerbations. Participants of this existing COPD cohort will also be asked to participate in the RESCEU study. An additional 50 subjects will be recruited from outpatient clinics during the coming months.

Participants of an ongoing COPD study at the UMCG will be invited to participate, in addition, in the RESCEU study. In addition, new subjects will be recruited at the department of pulmonology during outpatient clinics. Around 50 subjects have been included in the study of whom 34 have already had a baseline visit. Potential participants received information about the study and will be contacted in the coming months to confirm if they are willing to participate in the study. UMCG expects to recruit the additional 200 subjects for the RESCEU COPD cohort study before July 2018.

1. Introduction

The COPD cohort study is the fourth of the RESCEU clinical studies and will be conducted at Imperial College and UMCG. In this observational, prospective study, data and sample collection will be performed. The aim is to recruit five hundred subjects with COPD (GOLD stage I-IV) and follow them up for 3 RSV seasons to determine the incidence and severity of RSV medically attended respiratory illness in adults with COPD. At the start of the study and the end of the study participants will be characterized, including by FEV1 measurement. The participants will be followed by active surveillance through regular contacts. Cost, resource use and HRQoL data will be collected using questionnaires in addition to a daily symptom diary throughout the study period. RSV diagnosis will be based on respiratory samples at time of symptoms of an exacerbation and serology pre- and post-RSV season. To this end, nasal swabs and sputum will be collected at the time of exacerbations, with or without medical attention, for respiratory pathogen detection. Serum will be collected before and after the RSV season to measure a relevant increase in antibody titer during the RSV season. For biomarker studies, samples will be collected for analysis in WP5.

2. Methods

Clinically stable possible participants with COPD (GOLD Global Initiative for Chronic Obstructive Lung Disease [GOLD] Stage I-IV) will be recruited from the COPD clinic at UMCG and the London COPD cohort at Imperial College. The London COPD cohort is a rolling cohort of 200 patients who are trained in reporting of exacerbations. In London, further potential participants will be recruited from outpatient COPD clinics at the Royal Brompton Hospital and Imperial Healthcare NHS Trust. Patients will be identified as being suitable for recruitment by their treating physician and asked if they are willing to be contacted by the study team. These hospitals are the main study research sites. At the UMCG participants of an ongoing COPD study will be asked to also participate in the RESCEU study. In addition, new subjects will be recruited at the department of pulmonology during outpatient clinics. Potential eligible patients will be contacted and given a patient information sheet (PIS) describing the study in detail and inviting the patient to attend a hospital screening visit. Patients expressing an interest in participation will be offered a screening appointment at the hospital and informed consent will be obtained. The following inclusion and exclusion criteria will apply:

Inclusion criteria:
- Age ≥40 years at recruitment.
- Smoking history of >10 pack years.
- COPD patients with an FEV1/FVC <0.7.

Exclusion criteria:
- Patients with a history of asthma, significant bronchiectasis, carcinoma of the bronchus, or other significant respiratory disease.
- Patients taking immunosuppressive medications.
- Active cancer diagnosis.
- Long-term steroid therapy (≥10 mg/day).

For more information about the study design, see Deliverable 4.1 Annex IV. Clinical study 4: COPD cohort study protocol.

3. Results

Around half of the target number of study participants have already been recruited into the COPD cohort study:

Imperial: the 200 subjects of the existing COPD cohort will be asked informed consent to also participate in the RESCEU study. An additional 50 subjects will be recruited from outpatient clinics during the coming months.

UMCG: Around 50 subjects have been included in the study (until 31 October 2017) of whom 34 already had a baseline visit. Potential participants received information about the study and will be contacted in the coming months to confirm if they are willing to participate in the study. UMCG expects to recruit the additional 200 subjects for the RESCEU COPD cohort study before July 2018.

4. Conclusion and next steps

Imperial has an existing COPD cohort of 200 subjects who will be asked informed consent to also participate in the RESCEU COPD cohort study. 50 additional subjects will be recruited for the RESCEU COPD cohort study in the coming months.

UMCG has already recruited around 50 subjects and expects to recruit the additional 200 subjects for the RESCEU COPD cohort study before July 2018.